Growth hormone–releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2308342120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Jose M Condor Capcha und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136. Hauptthemen laut MEDLINE: COVID-19, Respiratory Distress Syndrome. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BLRD VA, NIH HHS, U.S. Department of Veterans Affairs.
Abstract (Originalsprache)
COVID-19 pneumonia causes acute lung injury and acute respiratory distress syndrome (ALI/ARDS) characterized by early pulmonary endothelial and epithelial injuries with altered pulmonary diffusing capacity and obstructive or restrictive physiology. Growth hormone–releasing hormone receptor (GHRH-R) is expressed in the lung and heart. GHRH-R antagonist, MIA-602, has been reported to modulate immune responses to bleomycin lung injury and inflammation in granulomatous sarcoidosis. We hypothesized that MIA-602 would attenuate rVSV-SARS-CoV-2-induced pulmonary dysfunction and heart injury in a BSL-2 mouse model. Male and female K18-h ACE2 tg mice were inoculated with SARS-CoV-2/USA-WA1/2020, BSL-2-compliant recombinant VSV-eGFP-SARS-CoV-2-Spike (rVSV-SARS-CoV-2), or PBS, and lung viral load, weight loss, histopathology, and gene expression were compared. K18-h ACE2 tg mice infected with rVSV-SARS-CoV-2 were treated daily with subcutaneous MIA-602 or vehicle and conscious, unrestrained plethysmography performed on days 0, 3, and 5 (n = 7 to 8). Five days after infection mice were killed, and blood and tissues collected for histopathology and protein/gene expression. Both native SARS-CoV-2 and rVSV-SARS-CoV-2 presented similar patterns of weight loss, infectivity (~60%), and histopathologic changes. Daily treatment with MIA-602 conferred weight recovery, reduced lung perivascular inflammation/pneumonia, and decreased lung/heart ICAM-1 expression compared to vehicle. MIA-602 rescued altered respiratory rate, increased expiratory parameters (Te, PEF, EEP), and normalized airflow parameters (Penh and Rpef) compared to vehicle, consistent with decreased airway inflammation. RNASeq followed by protein analysis revealed heightened levels of inflammation and end-stage necroptosis markers, including ZBP1 and pMLKL induced by rVSV-SARS-CoV-2, that were normalized by MIA-602 treatment, consistent with an anti-inflammatory and pro-survival mechanism of action in this preclinical model of COVID-19 pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Cardiology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136.
- Interdisciplinary Stem Cell Institute, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136.
- Department of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136.
- Research Service, Miami Veterans Affairs Health System (VAHS), Miami, FL 33125.
- Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Miami Miller School of Medicine, Miami, FL 33101.
- Department of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD 21205.
ORCID-Profile: Andrew Pekosz, Andrew V Schally
Förderung
- BLRD VA
- NIH HHS
- U.S. Department of Veterans Affairs
- HHS | NIH | National Heart, Lung, and Blood Institute
Zitieren
APA
Condor Capcha, J. M., Kamiar, A., Robleto, E., Saad, A. G., Cui, T., Wong, A., Villano, J., Zhong, W., Pekosz, A., Medina, E., Cai, R., Sha, W., Ranek, M. J., Webster, K. A., Schally, A. V., Jackson, R. M., & Shehadeh, L. A. (2023). Growth hormone–releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2308342120
Vancouver
Condor Capcha JM, Kamiar A, Robleto E, Saad AG, Cui T, Wong A, et al. Growth hormone–releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2308342120
BibTeX
@article{CondorCapcha2023,
author = {Condor Capcha, Jose M and Kamiar, Ali and Robleto, Emely and Saad, Ali G and Cui, Tengjiao and Wong, Amanda and Villano, Jason and Zhong, William and Pekosz, Andrew and Medina, Edgar and Cai, Renzhi and Sha, Wei and Ranek, Mark J and Webster, Keith A and Schally, Andrew V and Jackson, Robert M and Shehadeh, Lina A},
title = {Growth hormone–releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2308342120}
}
EUVIMED